Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
June 24 2019 - 4:05PM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced
the appointment of Lori Lyons-Williams to its Board of Directors.
Ms. Lyons-Williams is an industry leader with 20 years of
experience launching and commercializing innovative pharmaceutical
products.
“We welcome Lori to our board and look forward to her
contributions as we continue to build Five Prime by advancing our
differentiated clinical pipeline, leveraging our discovery
platform, and collaborating with our strategic alliance partners,”
said Aron Knickerbocker, Chief Executive Officer of Five Prime
Therapeutics. “Lori is an experienced executive with a demonstrated
track record of building high performing teams and successful
businesses. Her commercial experience will bring helpful
perspective as the team prepares to bring new therapies to
patients.”
"I am impressed by the management team and by the consistent
advancement of Five Prime’s robust clinical pipeline,” said Ms.
Lyons-Williams. “I am delighted to be joining this dedicated and
experienced team at a time when the pipeline is maturing and when
the management team is preparing for the next stage of the
company’s evolution.”
Ms. Lyons-Williams is currently the Chief Commercial Officer of
Dermira, Inc. where she is responsible for developing and
implementing the commercial strategy for Dermira’s lead product
candidates. Prior to Dermira, Ms. Lyons-Williams was Vice President
of Sales & Marketing for the Allergan Urology franchise. In
addition, Ms. Lyons-Williams held commercial leadership roles of
increasing responsibility in Allergan’s dermatology and
BOTOX® franchises.
In addition to her operational experience, Ms. Lyons-Williams
currently serves as a director and Vice Chair of the National
Association for Incontinence and previously served as a director of
Girls Inc. and the Orange County Business Council.
Ms. Lyons-Williams received a B.A. in Interdisciplinary Studies
with a Pre-Medicine Concentration from Virginia Tech and an M.B.A.
from the Carlson School of Management of the University of
Minnesota.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
protein therapeutics to improve the lives of patients with serious
diseases. Five Prime’s product candidates have innovative
mechanisms of action and address patient populations in need of
better therapies. The company focuses on researching and developing
immuno-oncology and targeted cancer therapies paired with companion
diagnostics to identify patients who are most likely to benefit
from treatment with Five Prime’s product candidates. Five Prime has
entered into strategic collaborations with leading global
pharmaceutical companies and has promising product candidates in
clinical and preclinical development. For more information, please
visit www.fiveprime.com or follow us on LinkedIn, Twitter and
Facebook.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Five Prime's
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Five Prime’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” contained therein. Except
as required by law, Five Prime assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Source: Five Prime Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190624005628/en/
Media and Investor Contact Martin Forrest VP, Investor
Relations & Corporate Communications Five Prime Therapeutics,
Inc. 415-365-5625 martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Oct 2023 to Oct 2024